Literature DB >> 20236262

Elevated NK cell cytotoxicity, CD158a expression in NK cells and activated T lymphocytes in peripheral blood of women with IVF failures.

Viktor P Chernyshov1, Iryna O Sudoma, Boris V Dons'koi, Anton A Kostyuchyk, Yulia V Masliy.   

Abstract

PROBLEM: The aim of this study was to evaluate the role of elevated natural killer cytotoxicity (NKc) in women with multiple implantation failures (IF) in vitro fertilization-embryo transfer (IVF-ET) cycles. METHODS OF STUDY: Seventy-nine antiphospholipid antibodies-negative women with IF including 33 women with elevated NKc were selected for investigation. K-562 cell line was used to evaluate NKc. Lymphocyte subsets, intracellular cytokines [interferon (IFN)-gamma, interleukin (IL)-4, tumour necrosis factor, IL-10], expression of activating markers [CD69, human leukocyte antigen (HLA)-DR], CD8, KIR (CD158a), CD95, and chemokine receptors (CXCR3, CCR4) were estimated by flow cytometry.
RESULTS: In women with IF, levels of NKc were higher than in IVF successful women. IF was associated with higher expression of CD8, CD158a, and HLA-DR in NK cells, activating markers in T lymphocytes, and lower levels of CCR4+ and IL-4+ T lymphocyte subsets. Predictive value of single elevated NKc for IVF success was 0.85, but addition of two other abnormal parameters resulted in its decrease to <0.39.
CONCLUSIONS: Elevated NKc is negative factor, though not critical for implantation in IVF cycles. Immune mechanism of IVF failure includes not only elevated NKc but also some other factors, such as elevated expression of CD8 and CD158a on NK cells, T lymphocyte activation, and diminished T helper 2 parameters.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20236262     DOI: 10.1111/j.1600-0897.2010.00825.x

Source DB:  PubMed          Journal:  Am J Reprod Immunol        ISSN: 1046-7408            Impact factor:   3.886


  6 in total

Review 1.  NK cell abnormality and its treatment in women with reproductive failures such as recurrent pregnancy loss, implantation failures, preeclampsia, and pelvic endometriosis.

Authors:  Atsushi Fukui; Mai Kamoi; Ayano Funamizu; Kohei Fuchinoue; Hitomi Chiba; Megumi Yokota; Rie Fukuhara; Hideki Mizunuma
Journal:  Reprod Med Biol       Date:  2015-04-11

2.  Accentuated Peripheral Blood NK Cytotoxicity Forms an Unfavorable Background for Embryo Implantation and Gestation.

Authors:  Boris Dons'koi; Oksana Onyshchuk; Iryna Kononenko; Vira Sirenko; Natalia Bodnar; Andrii Serbyn; Anzhela Kozachok; Yulia Brovarska; Dariia Osypchuk; Yaroslava Anochko; Viktor Chernychov
Journal:  Diagnostics (Basel)       Date:  2022-04-06

3.  shRNA-Induced Knockdown of a Bioinformatically Predicted Target IL10 Influences Functional Parameters in Spontaneously Hypertensive Rats with Asthma.

Authors:  Tatiana Drevytska; Roman Morhachov; Lesya Tumanovska; Georgiy Portnichenko; Vasyl Nagibin; Oleksiy Boldyriev; Tatiana Lapikova-Bryhinska; Veronika Gurianova; Borys Dons'koi; Maxim Freidin; Vladimir Ivanisenko; Elena Yu Bragina; Ralf Hofestädt; Victor Dosenko
Journal:  J Integr Bioinform       Date:  2018-12-10

4.  Comparison of T and NK lymphocyte subsets between human endometrial tissue and peripheral blood.

Authors:  Viktor P Chernyshov; Boris V Dons'koi; Iryna O Sudoma; Yana O Goncharova
Journal:  Cent Eur J Immunol       Date:  2019-09-30       Impact factor: 2.085

5.  Natural killer frequency determines natural killer cytotoxicity directly in accentuated zones and indirectly in "moderate-to-normal frequency" segment.

Authors:  Boris V Dons'koi; Victor P Chernyshov; Dariia V Osypchuk; Irina Sudoma; Kseniia G Khazhylenko; Galina V Strelko; Wera J Sirenko
Journal:  Cent Eur J Immunol       Date:  2020-11-01       Impact factor: 2.085

6.  Association between microRNA machinery gene polymorphisms and recurrent implantation failure.

Authors:  Yubin Lee; Eun Hee Ahn; Chang Soo Ryu; Jung Oh Kim; Hui Jeong An; Sung Hwan Cho; Ji Hyang Kim; Young Ran Kim; Woo Sik Lee; Nam Keun Kim
Journal:  Exp Ther Med       Date:  2020-02-26       Impact factor: 2.447

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.